GLP3-RT 60mg is a synthetic research peptide corresponding to retatrutide (research designation LY3437943), supplied by Echo Peptides for laboratory and in-vitro research use only. It is engineered as a single-molecule triple agonist with structural affinity for the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, incorporating a fatty acid conjugate that researchers associate with extended structural stability in experimental preparations.
As a unified multi-receptor reference compound, GLP3-RT is used in cell-culture and preclinical model systems to probe how convergent incretin and glucagon signaling can be studied within a single agonist scaffold. Its combined receptor profile makes it a distinctive tool for investigators comparing mono-, dual-, and tri-agonist behavior across metabolic pathways in controlled in-vitro settings.
Key research areas
- Multi-receptor metabolic signaling and energy-expenditure models studied in cell-culture and preclinical systems
- Glucose homeostasis and appetite-regulation pathways as experimental research endpoints
- Lipid metabolism and body-composition paradigms in in-vitro and preclinical models
- Comparative incretin plus glucagon receptor signaling and downstream cascade studies
- Structure-stability investigations relating to fatty-acid-conjugated peptide agonists
Specifications
- Compound: GLP3-RT (retatrutide, research designation LY3437943)
- Amount: 60mg per vial
- Form: Lyophilized white powder
- Modifications: Triple GIP/GLP-1/glucagon receptor agonist with fatty acid conjugate
- Solubility: Soluble in bacteriostatic water or research buffers for reconstitution
- Storage: Refrigerate at 2–8°C; long-term stability when lyophilized
Each batch is third-party tested for identity and purity, and a Certificate of Analysis is available. This product is intended for laboratory and in-vitro research use only; it is not for human or veterinary use and not for diagnostic or therapeutic purposes.
